Product
Corticosteroids
Aliases
Corticosteroids (CS), Prednisone® /Prednisolone®
Name
Corticosteroids
24 clinical trials
1 drug
23 indications
Indication
Primary Immune ThrombocytopeniaIndication
Kidney TransplantIndication
Transplant RejectionIndication
Duchenne muscular dystrophyIndication
Graft-Versus-Host DiseaseIndication
AcuteIndication
Thrombotic Thrombocytopenic PurpuraIndication
Chronic Graft-versus-host diseaseIndication
Liver TransplantIndication
kidney transplantIndication
Acute Graft-versus-host DiseaseIndication
Hairy Cell LeukemiaIndication
Oral Lichen PlanusIndication
Myasthenia GravisIndication
Chronic Obstructive Pulmonary DiseaseIndication
Renal Allograft RecipientsIndication
Acute Graft Versus Host DiseaseIndication
Severe Checkpoint Inhibitor PneumonitisIndication
Acute Postoperative PainIndication
Lung TransplantIndication
AllograftsIndication
ulcerative colitisIndication
ChildhoodDrug
corticosteroidsClinical trial
A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)Status: Recruiting, Estimated PCD: 2025-09-25
Clinical trial
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients: A Randomized, Open-label, Multicenter Clinical TrialStatus: Completed, Estimated PCD: 2022-07-15
Clinical trial
A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.Status: Recruiting, Estimated PCD: 2024-11-14
Clinical trial
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant RecipientsStatus: Completed, Estimated PCD: 2023-10-03
Clinical trial
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)Status: Terminated, Estimated PCD: 2023-02-13
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host DiseaseStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraStatus: Recruiting, Estimated PCD: 2024-12-13
Clinical trial
A 60 Month, Single-arm, Proof-of-concept Study to Induce Allogeneic Tolerance in Deceased Donor Liver Transplant Recipients Using Siplizumab, an Anti-CD2 Antibody in Combination With Cyclophosphamide and SplenectomyStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseStatus: Not yet recruiting, Estimated PCD: 2027-03-05
Clinical trial
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant RecipientsStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric SubjectsStatus: Terminated, Estimated PCD: 2020-02-17
Clinical trial
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)Status: Active (not recruiting), Estimated PCD: 2023-06-28
Clinical trial
A Comparative, Open-label Study to Evaluate Graft Function in de Novo Renal Allograft Recipients Treated With Either a 'Reduced Dose' or a 'Standard Dose' of Cyclosporine in Combination With Sirolimus and CorticosteroidsStatus: Completed
Clinical trial
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaStatus: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
Evaluation of the Efficacy of Supplementary Probiotic Capsules With Topical Clobetasol Propionate 0.05% in the Treatment of Oral Lichen PlanusStatus: Recruiting, Estimated PCD: 2023-10-30
Clinical trial
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.Status: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
Determining Optimal Dose of Corticosteroids in COPD Exacerbations: A Pilot StudyStatus: Terminated, Estimated PCD: 2020-03-15
Clinical trial
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsStatus: Recruiting, Estimated PCD: 2026-05-25
Clinical trial
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
The Efficacy and Safety of Corticosteroids in Combination With Biological Agents in the Management of Severe Immune Related Adverse Events Cohort A: The Efficacy and Safety of Corticosteroids or Corticosteroids Combination With Ruxolitinib in Patients With Severe Checkpoint Inhibitor PneumoniaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Various Strategies to Reduce Acute Post Hemorrhoidectomy Pain: A Comparative StudyStatus: Active (not recruiting), Estimated PCD: 2024-07-14
Clinical trial
A Scandinavian Controlled, Randomized, Open-label, and Multi-centre Study Evaluating if Once-daily Tacrolimus or Twice-daily Cyclosporin, Reduces the 3-year Incidence of Chronic Lung Allograft Dysfunction After Lung TransplantationStatus: Active (not recruiting), Estimated PCD: 2025-10-30
Clinical trial
First-line Treatment With Infliximab Versus Corticosteroids in Children With Newly Diagnosed Moderate to Severe Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-06-01